Table 2. Results from the comparisons of biomarker levels between AF and no AF in each phase of the biomarker study.
| Name | Uniprot | Discovery (n = 26) | Phase I Verification (n = 96) |
Phase II Validation (n = 178) |
||
|---|---|---|---|---|---|---|
| p value | FDR | Fold change | P-value | P-value | ||
| N-terminal pro-BNP* | P16860 | 0.001 | 0.986 | 2.487 | <0.001 | 0.102 |
| Dermatopontin (DPT) | Q07507 | 0.008 | 0.986 | -0.568 | 0.758 | - |
| Interleukin-1 receptor-like 1 (ST-2) | Q01638 | 0.015 | 0.986 | 0.880 | 0.064$ | 0.123 |
| Coagulation factor IX (FIX) | P00740 | 0.015 | 0.986 | -0.292 | 0.015 | - |
| Metalloproteinase inhibitor 2 (TIMP-2) | P16035 | 0.019 | 0.986 | 0.245 | 0.097$ | 0.823 |
| Beta-endorphin | P01189 | 0.026 | 0.986 | -0.419 | 0.628 | - |
| Interleukin-1 receptor antagonist protein (IL1RA) | P18510 | 0.026 | 0.986 | -0.447 | 0.311 | - |
| C-C motif chemokine 3-like 1(CC3L1) | P16619 | 0.027 | 0.986 | 0.253 | 0.262$ | - |
| Interleukin-36 alpha (IL36-A) | Q9UHA7 | 0.031 | 0.986 | 0.491 | 0.207$ | - |
| Polymeric immunoglobulin receptor (PIGR) | P01833 | 0.033 | 0.986 | 0.579 | 0.242$ | - |
| Low affinity immunoglobulin gamma Fc region receptor II-a (FcgR-IIa) | P12318 | 0.038 | 0.986 | 1.141 | 0.111$ | - |
| Bone morphogenetic protein 1 (BMP1) | P13497 | 0.039 | 0.986 | -0.287 | 0.937 | - |
*NT-proBNP was already tested in Phase I as part of another study [7].